新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 诺华 » 英国将推广诺华乙型脑膜炎疫苗

英国将推广诺华乙型脑膜炎疫苗

来源:生物谷 2014-03-23 16:28

2014年3月23日讯 /生物谷BIOON/ --英国The Joint Committee on Vaccination and Immunisation (JCVI)最近宣布英国将推广乙型脑膜炎疫苗Bexsero以控制这种致命疾病在英国国内的传播。事实上,从去年开始JCVI就已经推动政府进行这方面的调研。目前在英国每年有1760人感染乙型脑膜炎,每十名患者中就有一名死亡。同时这种疾病还会留下许多严重的后遗症。

乙型脑膜炎多发于一岁以下婴儿,而5-6个月大的婴儿更是易感人群。此次英国开始推广这种疫苗后,预计今后每年会有70万名婴儿接种。

事实上,此前市面上没有针对乙型脑膜炎的疫苗,此次诺华公司新开发的Bexsero疫苗是迄今唯一一种能够保护接种者不受乙型脑膜炎的疫苗。(生物谷Bioon.com)

详细英文报道:

A vaccine that protects against a deadly form of meningitis is set to be introduced in the UK.

The Joint Committee on Vaccination and Immunisation (JCVI), which has recommended the move to the government, had said last year that the jab was not cost-effective.

Meningitis charities said more data had led to today's decision, and it was a "wonderful outcome".

About 1,760 people contract meningitis B each year and one in 10 dies.

Babies under one year are most at risk of meningitis B, and the cases peak at around five or six months of age.

The bacterial infection causes inflammations of the brain and spinal cord.

It leaves around a third with life-altering effects, such as brain damage or limb loss.

The JCVI said the vaccine was effective in preventing meningitis B and should be rolled out subject to it being made available by the manufacturer "at a cost effective price".

It has recommended the jab be added to the existing immunisation schedule, starting at two months of age.

Around 700,000 infants will be eligible for vaccination each year.

'First in the world'

There are vaccines against other forms of meningitis but the Bexsero jab, developed by Novartis, is the only one thought to protect against meningitis B.

Tests have suggested the vaccine is effective against 73% of the different strains of the disease. It was licensed for use in Europe in January 2013.

The JCVI considered the introduction of the meningitis B vaccine last summer but in an interim judgement, it ruled it would not be cost-effective to introduce it.

At the time, campaigners called the decision a "severe blow" and urged the committee to look at the issue again.

More evidence has since been submitted, and the government will now begin negotiations with Novartis over the cost of the vaccine.

Novartis said it was "ready to supply" the vaccine as soon as the Department of Health had all the necessary processes in place,

Prof Andrew Pollard, chairman of the JCVI and professor of paediatric infection and immunity at the University of Oxford said: "MenB disproportionately affects babies and young children and can be devastating.

'Complex and brave decision'

"After very careful consideration, JCVI concluded that use of the new vaccine would reduce cases of meningococcal meningitis and septicaemia and lead to a reduction in deaths, limb amputations and brain injury caused by the disease.

"Today the JCVI published its recommendation to the UK health departments that if the new vaccine can be purchased at a low price and is therefore cost effective for the NHS, it should be used in the routine immunisation programme for babies in the UK to prevent disease.

"Routine use of the MenB vaccine is expected to make an important contribution to the health of our population."

The deputy chief medical officer, Prof John Watson, said: "We will now be working closely with Novartis in the coming months and if negotiations are successful, we hope to work with the other UK health departments to introduce a vaccine to prevent MenB as quickly as possible.

"This would make the UK the first country in the world to implement a nationwide vaccination programme."

Adam Finn, a vaccine expert and professor of paediatrics at the University of Bristol, said: "This was a complex, difficult and brave decision with far reaching consequences not only for the control of meningococcal disease but also for future vaccine development against severe but rare infections."

Christopher Head, chief executive of Meningitis Research Foundation said: "We are delighted that the JCVI have recommended vaccinating all babies against this most feared and deadly disease.

"It's a wonderful outcome which will save lives and spare countless families the trauma of seeing a loved one seriously disabled by the devastating after effects of MenB."

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库